Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness

References

• Cohn AC , MacNeil JR , Harrison LH , et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control . Surveillance of invasive bacterial diseases in Europe. Available from: www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1261 [Last accessed 19 February 2015]
   Google Scholar
• MacLennan J , Kafatos G , Neal K , et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006;12:950-7
   PubMed Web of Science ®Google Scholar
• Tapsall J . Annual report of the Australian meningococcal surveillance programme, 2008. Commun Dis Intell 2009;33:259-67
   Google Scholar
• Finne J , Leinonen M , Mäkelä PH . Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7
   PubMed Web of Science ®Google Scholar
• Brendish NJ , Read RC . Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine. Expert Rev Vaccines 2015;14:493-503
   PubMed Web of Science ®Google Scholar
• Seib KL , Scarselli M , Comanducci M , et al. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines 2015;14(6):841-59
   PubMed Web of Science ®Google Scholar
• Howitz M , Krause TG , Simonsen JB , et al. Lack of association between group B meningococcal disease and autoimmune disease. Clin Infect Dis 2007;45:1327-34
   PubMed Web of Science ®Google Scholar
• Poolman JT , Hopman CT , Zanen HC . Immunogenicity of meningococcal antigens as detected in patient sera. Infect Immun 1983;40:398-406
   PubMed Web of Science ®Google Scholar
• Kortekaas J , Müller SA , Ringler P , et al. Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA). Microbes Infect Inst Pasteur 2006;8:2145-53
   PubMed Web of Science ®Google Scholar
• Weynants VE , Feron CM , Goraj KK , et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007;75:5434-42
   PubMed Web of Science ®Google Scholar
• Frasch CE , Zollinger WD , Poolman JT . Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985;7:504-10
   PubMedGoogle Scholar
• Jolley KA , Brehony C , Maiden MCJ . Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007;31:89-96
   PubMed Web of Science ®Google Scholar
• Saukkonen K , Leinonen M , Abdillahi H , Poolman JT . Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989;7:325-8
   PubMed Web of Science ®Google Scholar
• Tappero JW , Lagos R , Ballesteros AM , et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-7
   PubMed Web of Science ®Google Scholar
• Pettersson A , Kuipers B , Pelzer M , et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun 1990;58:3036-41
   PubMed Web of Science ®Google Scholar
• Urwin R , Russell JE , Thompson EAL , et al. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004;72:5955-62
   PubMed Web of Science ®Google Scholar
• Thompson EAL , Feavers IM , Maiden MCJ . Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiol Read Engl 2003;149:1849-58
   PubMed Web of Science ®Google Scholar
• Acevedo R , Fernández S , Zayas C , et al. Bacterial Outer Membrane Vesicles and Vaccine Applications. Front Immunol 2014;5:121
   PubMed Web of Science ®Google Scholar
• Bjune G , Høiby EA , Grønnesby JK , et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6
   PubMed Web of Science ®Google Scholar
• Sierra GV , Campa HC , Varcacel NM , et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207
   PubMedGoogle Scholar
• Holst J , Martin D , Arnold R , et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(Suppl 2):B3-12
   PubMed Web of Science ®Google Scholar
• Noronha CP , Struchiner CJ , Halloran ME . Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 1995;24:1050-7
   PubMed Web of Science ®Google Scholar
• De Moraes JC , Perkins BA , Camargo MC , et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8
   PubMed Web of Science ®Google Scholar
• Kelly C , Arnold R , Galloway Y , O’Hallahan J . A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-23
   PubMed Web of Science ®Google Scholar
• Taha MK , Zarantonelli ML , Alonso JM , et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007;25:2537-8
   PubMed Web of Science ®Google Scholar
• Caron F , du Châtelet IP , Leroy JP , et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Di 2011;11:455-63
   PubMed Web of Science ®Google Scholar
• Martin DR , Walker SJ , Baker MG , Lennon DR . New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998;177:497-500
   PubMed Web of Science ®Google Scholar
• Milagres LG , Ramos SR , Sacchi CT , et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-24
   PubMed Web of Science ®Google Scholar
• Holst J , Oster P , Arnold R , et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccines Immunother 2013;9:1241-53
   PubMed Web of Science ®Google Scholar
• Nøkleby H , Aavitsland P , O’Hallahan J , et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007;25:3080-4
   PubMed Web of Science ®Google Scholar
• Stehr-Green P , Radke S , Kieft C , et al. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 2008;26:739-42
   PubMed Web of Science ®Google Scholar
• Tondella ML , Popovic T , Rosenstein NE , et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000;38:3323-8
   PubMed Web of Science ®Google Scholar
• Boutriau D , Poolman J , Borrow R , et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007;14:65-73
   PubMed Web of Science ®Google Scholar
• Claassen I , Meylis J , van der Ley P , et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14:1001-8
   PubMed Web of Science ®Google Scholar
• van der Ley P , van der Biezen J , Poolman JT . Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995;13:401-7
   PubMed Web of Science ®Google Scholar
• Cartwright K , Morris R , Rümke H , et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-19
   PubMed Web of Science ®Google Scholar
• Peeters CC , Rümke HC , Sundermann LC , et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-15
   PubMed Web of Science ®Google Scholar
• De Kleijn ED , de Groot R , Labadie J , et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000;18:1456-66
   PubMed Web of Science ®Google Scholar
• Luijkx TA , van Dijken H , Hamstra H-J , et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 2003;71:6367-71
   PubMed Web of Science ®Google Scholar
• van der Ley P , Steeghs L , Hamstra HJ , et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001;69:5981-90
   PubMed Web of Science ®Google Scholar
• Van de Waterbeemd B , Zomer G , Kaaijk P , et al. Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis. PLoS One 2013;8:e65157
   PubMed Web of Science ®Google Scholar
• van der Ley P , van den Dobbelsteen G . Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 2011;7:886-90
   PubMed Web of Science ®Google Scholar
• Koeberling O , Giuntini S , Seubert A , Granoff DM . Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009;16:156-62
   PubMed Web of Science ®Google Scholar
• Keiser PB , Biggs-Cicatelli S , Moran EE , et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011;29:1413-20
   PubMed Web of Science ®Google Scholar
• Van de Waterbeemd B , Streefland M , van der Ley P , et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010;28:4810-16
   PubMed Web of Science ®Google Scholar
• Kaaijk P , van Straaten I , van de Waterbeemd B , et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013;31:1065-71
   PubMed Web of Science ®Google Scholar
• Welsch JA , Ram S , Koeberling O , Granoff DM . Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008;197:1053-61
   PubMed Web of Science ®Google Scholar
• Giuntini S , Reason DC , Granoff DM . Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 2011;79:3751-9
   PubMed Web of Science ®Google Scholar
• Pajon R , Beernink PT , Harrison LH , Granoff DM . Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010;28:2122-9
   PubMed Web of Science ®Google Scholar
• Neisseria Factor H binding protein sequence typing. 2014. Available from: http://pubmlst.org/neisseria/fHbp/ [Last accessed 10 November 2014]
   Google Scholar
• Jiang H-Q , Hoiseth SK , Harris SL , et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010. Available from: www.ncbi.nlm.nih.gov/pubmed/20619376 [Last accessed 26 July 2010]
   Google Scholar
• Richmond PC , Nissen MD , Marshall HS , et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012;30:6163-74
   PubMed Web of Science ®Google Scholar
• Richmond PC , Marshall HS , Nissen MD , et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12:597-607
   PubMed Web of Science ®Google Scholar
• Marshall HS , Richmond PC , Nissen MD , et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013;31:1569-75
   PubMed Web of Science ®Google Scholar
• Nissen MD , Marshall HS , Richmond PC , et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013;32:364-71
   PubMed Web of Science ®Google Scholar
• Marshall HS , Richmond PC , Nissen MD , et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012;31:1061-8
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F , Gimenez-Sanchez F , Bernaola-Iturbe E , et al. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine 2014;32:5206-11
   PubMed Web of Science ®Google Scholar
• Murphy E , Andrew L , Lee K-L , et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200:379-89
   PubMed Web of Science ®Google Scholar
• Hoiseth SK , Murphy E , Andrew L , et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013;32:1096-101
   PubMed Web of Science ®Google Scholar
• Boan P , Metasan N , Tempone S , et al. Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011. BMC Infect Dis 2014;14:686
   PubMed Web of Science ®Google Scholar
• De Filippis I , de Lemos APS , Hostetler JB , et al. Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil. PLoS One 2012;7:e33016
   PubMed Web of Science ®Google Scholar
• Findlow J , Borrow R , Snape MD , et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37
   PubMed Web of Science ®Google Scholar
• Snape MD , Dawson T , Oster P , et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-9
   PubMed Web of Science ®Google Scholar
• Granoff DM , Costa I , Konar M , et al. Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine. J Infect Dis 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Costa I , Pajon R , Granoff DM . Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio 2014;5:e01625-14
   PubMed Web of Science ®Google Scholar
• Toneatto D , Ismaili S , Ypma E , et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011;7:646-53
   PubMed Web of Science ®Google Scholar
• Pizza M , Scarlato V , Masignani V , et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20
   PubMed Web of Science ®Google Scholar
• Bos MP , Grijpstra J , Tommassen-van Boxtel R , Tommassen J . Involvement of neisseria meningitidis lipoprotein GNA2091 in the assembly of a subset of outer membrane proteins. Biol Chem 2014;289:105602-10
   Web of Science ®Google Scholar
• Giuliani MM , Adu-Bobie J , Comanducci M , et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9
   PubMed Web of Science ®Google Scholar
• Sadarangani M , Pollard AJ . Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010;10:112-24
   PubMed Web of Science ®Google Scholar
• Comanducci M , Bambini S , Caugant DA , et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004;72:4217-23
   PubMed Web of Science ®Google Scholar
• Vogel U , Taha M-K , Vazquez JA , et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13:416-25
   PubMed Web of Science ®Google Scholar
• Wang X , Cohn A , Comanducci M , et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011;29:4739-44
   PubMed Web of Science ®Google Scholar
• Fagnocchi L , Biolchi A , Ferlicca F , et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun 2013;81:560-9
   PubMed Web of Science ®Google Scholar
• Welsch JA , Moe GR , Rossi R , et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003;188:1730-40
   PubMed Web of Science ®Google Scholar
• Serruto D , Spadafina T , Ciucchi L , et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010;107:3770-5
   PubMed Web of Science ®Google Scholar
• Vu DM , Wong TT , Granoff DM . Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 2011;29:1968-73
   PubMed Web of Science ®Google Scholar
• Vesikari T , Esposito S , Prymula R , et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35
   PubMed Web of Science ®Google Scholar
• Giuliani MM , Biolchi A , Serruto D , et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010;28:5023-30
   PubMed Web of Science ®Google Scholar
• Wong SH , Lennon DR , Jackson CM , et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009;28:385-90
   PubMed Web of Science ®Google Scholar
• O’Ryan M , Stoddard J , Toneatto D , et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs 2014;74:15-30
   PubMed Web of Science ®Google Scholar
• Jafri RZ , Ali A , Messonnier NE , et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013;11:17
   PubMed Web of Science ®Google Scholar
• Protection AGD of HO of H . Meningococcal - Australian Meningococcal Surveillance Programme annual reports. Available from: www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-menganrep.htm [Last accessed 15 May 2014]
   Google Scholar
• Trotter CL , Chandra M , Cano R , et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007;31:27-36
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention . Active bacterial core surveillance (ABCs). Available from: www.cdc.gov/abcs/reports-findings/surv-reports.html [Last accessed 07 April 2015]
   Google Scholar
• Hausdorff WP , Siber G , Paradiso PR . Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001;357:950-2
   PubMed Web of Science ®Google Scholar
• Harrison LH , Jolley KA , Shutt KA , et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006;193:1266-74
   PubMed Web of Science ®Google Scholar
• Bai X , Borrow R . Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010;9:1203-17
   PubMed Web of Science ®Google Scholar
• Swartley JS , Marfin AA , Edupuganti S , et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-6
   PubMed Web of Science ®Google Scholar
• Christensen H , May M , Bowen L , et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:853-61
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M , Wolter J , Hogea C , Vyse A . Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011;9:761-74
   PubMed Web of Science ®Google Scholar
• Pollard AJ , Riordan A , Ramsay M . Group B meningococcal vaccine: recommendations for UK use. Lancet 2014;383:1103-4
   PubMed Web of Science ®Google Scholar
• Shepard CW , Ortega-Sanchez IR , Scott RD II , et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005;115:1220-32
   PubMed Web of Science ®Google Scholar
• Read RC , Baxter D , Chadwick DR , et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-31
   PubMed Web of Science ®Google Scholar
• Henckaerts I , Durant N , De Grave D , et al. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007;25:2518-27
   PubMed Web of Science ®Google Scholar
• Borrow R , Andrews N , Goldblatt D , Miller E . Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69:1568-73
   PubMed Web of Science ®Google Scholar
• Andrews N , Borrow R , Miller E . Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10:780-6
   PubMedGoogle Scholar
• Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011;86:521-39
   PubMedGoogle Scholar
• Holst J , Feiring B , Fuglesang JE , et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7
   PubMed Web of Science ®Google Scholar
• Borrow R , Carlone GM , Rosenstein N , et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-107
   PubMed Web of Science ®Google Scholar
• Zollinger WD , Mandrell RE . Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983;40:257-64
   PubMed Web of Science ®Google Scholar
• Plikaytis BD , Stella M , Boccadifuoco G , et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012;19:1609-17
   PubMed Web of Science ®Google Scholar
• Medini D , Stella M , Wassil J . MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine 2015;33:2629-36
   PubMed Web of Science ®Google Scholar
• Bettinger JA , Scheifele DW , Halperin SA , et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013;32:124-30
   PubMed Web of Science ®Google Scholar
• Budroni S , Kleinschmidt A , Ypma E , et al. Pooled hSBA titers predict seroresponse rates of infants vaccinated with 4CMenB. 2014 IPNC proceedings. 2014. Available from: http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf
   Google Scholar
• Frosi G , Biolchi A , Lo Sapio M , et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31:4968-74
   PubMed Web of Science ®Google Scholar
• Abad R , Biolchi A , Moschioni M , et al. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB. Clin Vaccine Immunol 2015;22:357-60
   PubMed Web of Science ®Google Scholar
• Donnelly J , Medini D , Boccadifuoco G , et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5
   PubMed Web of Science ®Google Scholar
• McNeil LK , Zagursky RJ , Lin SL , et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013;77:234-52
   PubMed Web of Science ®Google Scholar
• Lennon D , Reid S , Stewart J , et al. Reducing inequalities with vaccines: New Zealand’s MeNZB vaccine initiative to control an epidemic. J Paediatr Child Health 2012;48:193-201
   PubMed Web of Science ®Google Scholar
• Watkins ER , Maiden MC . Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database. PLoS One 2012;7:e45349
   PubMed Web of Science ®Google Scholar
• Wang X , Shutt KA , Vuong JT , et al. Changes in the population structure of invasive neisseria meningitidis in the united states after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis 2015;211(12):1887-94
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP , Kriz P , Tzanakaki G , et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004;42:5146-53
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP , Caugant DA . Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004;53:821-32
   PubMed Web of Science ®Google Scholar
• Bratcher HB , Corton C , Jolley KA , et al. A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes. BMC Genomics 2014;15:1138
   PubMed Web of Science ®Google Scholar
• Altindis E , Cozzi R , Di Palo B , et al. Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery. Mol Cell Proteomics 2015;14:418-29
   PubMed Web of Science ®Google Scholar